FY2029 EPS Forecast for Xeris Biopharma Decreased by Analyst

Key Points

• HC Wainwright cut its FY2029 EPS estimate for Xeris Biopharma to $0.63 from $0.65, while maintaining a Buy rating and an $18 price target.
• Xeris beat quarterly expectations, reporting EPS of $0.06 versus $0.03 forecast and revenue of $107.23 million versus $101.68 million expected.
• Analyst views are mixed: the stock has a “Moderate Buy” consensus rating and a $16.20 average target, while Piper Sandler remains Neutral despite raising its target to $12.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Analysts at HC Wainwright dropped their FY2029 earnings per share estimates for shares of Xeris Biopharma in a research note issued to investors on Friday, November 6th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.63 per share for the year, down from their prior estimate of $0.65. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is $0.07 per share.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The company had revenue of $107.23 million for the quarter, compared to analysts' expectations of $101.68 million. Xeris Biopharma had a positive return on equity of 429.43% and a negative net margin of 1.76%.

Other equities research analysts have also issued reports about the stock. Oppenheimer restated an "outperform" rating and issued a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Piper Sandler reaffirmed a "neutral" rating and issued a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Leerink Partners increased their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a report on Thursday, September 10th. Weiss Ratings cut shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $16.20.

Xeris Biopharma Price Performance

Shares of XERS opened at $15.20 on Monday. Xeris Biopharma has a 1 year low of $5.25 and a 1 year high of $15.21. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The stock has a 50 day simple moving average of $9.62 and a two-hundred day simple moving average of $7.62. The firm has a market cap of $2.78 billion, a P/E ratio of -303.94 and a beta of 0.61.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently made changes to their positions in the business. Vilga Financial Planning LLC purchased a new stake in shares of Xeris Biopharma in the 3rd quarter worth about $10,134,000. Legal & General Group Plc bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $15,941,000. Walleye Capital LLC bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $4,841,000. Canada Pension Plan Investment Board bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $1,736,000. Finally, Bank of America Corp DE purchased a new position in shares of Xeris Biopharma during the second quarter valued at about $11,065,000. 42.75% of the stock is currently owned by institutional investors.

Insider Transactions at Xeris Biopharma

In related news, insider Steven Pieper sold 5,000 shares of the business's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $51,150.00. Following the transaction, the insider owned 1,346,053 shares in the company, valued at $13,770,122.19. The trade was a 0.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the transaction, the insider directly owned 1,086,130 shares of the company's stock, valued at $11,111,109.90. The trade was a 2.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 173,332 shares of company stock worth $1,721,471. Company insiders own 4.35% of the company's stock.

Key Stories Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing's syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.